Julphar announces its entry into the oncology market through a licence and supply agreement with Russia's BIOCAD
UAE-based Julphar, one of the largest pharmaceutical manufacturers in the Middle East and Africa, has announced its entry into the oncology market through a licence and supply agreement with Russian biotechnology company, BIOCAD.
Julphar said it will be partnering with BIOCAD and health authorities to register three specialized products to the UAE, which are used to treat breast cancer, B-cell non-Hodgkin's lymphoma, chronic lymphocytic leukemia, colon cancer, lung cancer and glioblastoma.
Jerome Carle, general manager of Julphar, said: “We are delighted to be partnering with BIOCAD in the UAE market as they have a proven track record and they support our core values. Entering the oncology market is a huge step forward for Julphar.
“It will enable us to continue to focus on delivering healthcare solutions that make a real difference to people’s lives.”
Cancer is one of the biggest health burdens in the UAE. According to a report issued last month by the World Health Organization’s (WHO) International Agency for Research on Cancer (IARC), breast cancer accounted for more than 20 percent of the total 4,707 new cancer cases that were found in the UAE in 2018.
“Cancer can be a very costly illness, placing a considerable financial burden on families,” said Carle.
“With the launch of these products in the local market, we would like to ensure that as many people as possible have access to life-saving medicines. When patients choose Julphar they can rest assured that they are consistently receiving high quality, safe and effective products.”